TOPICS
First-line maintenance Approaches | Response & Response Duration
Aggressive Approaches | Survival
TOPIC SEARCH: First-line | Response & Duration | Survival
Also see Refractory
|
First-line
maintenance
Return to top
|
1a. Current treatment of follicular and low-grade non-Hodgkin's lymphoma. Anticancer Drugs. 2001 Jun;12 Suppl 2:S5-9. Review. PMID: 11508934 abstract | Related_abstracts
2a. Quality of life in patients with low-grade non-Hodgkin's lymphoma.
Oncology (Huntingt). 1998 May;12(5):697-714; discussion 714, 717, 721. Review.
PMID: 9597680 abstract
3a. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial. abstract
4a. Vaccine Therapies for Non-Hodgkin's Lymphoma. Curr Treat Options Oncol. 2002 Aug;3(4):307-15. PMID: 12074767 PubMed
|
Response & Response Duration
Return to top
|
1b. Each Subsequent Therapy Results in Diminishing Response Rate and Duration of Response in Low Grade or Transformed Low Grade Non-Hodgkin's Lymphoma. ASCO 2001 Abstract 1165
3b. Stage III follicular lymphoma: long-term follow-up and patterns of failure.
Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):748-54 PMID: 14529780
|
Aggressive approaches
with the goal of achieving molecular remissions, long-term disease-free survival, and possible cures
There is hope that the following types of therapies may cure some patients with indolent NHL in some treatment settings
Note: For aggressive NHL, the goal of initial treatment is to cure.
CHOP + Rituxan
Transplants
Therapeutic vaccines
Radiotherapy
Other combinations
Return to top
|
1c. Can we cure indolent lymphomas? Clin Cancer Res. 1997 Dec;3(12 Pt 2):2655-9. Review. PMID: 10068269 PubMed
2c. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Semin Oncol. 2002 Feb;29(1 Suppl 2):36-40. PMID: 11842387 PubMed
3c. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001 Dec 15;98(13):3595-9 PubMed
4c. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999 Oct;5(10):1171-7. PMID: 10502821 PubMed
5c. Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. Eur J Haematol. 2002 Mar;68(3):144-9. PMID: 12068794 PubMed
6c. Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. [in patients with nodal bulky disease] - Eur J Haematol 2002: 68: 144-149 PDF | PDFHelp
7c. Mitoxantrone-cyclophosphamide-rituximab: an effective and safe combination for indolent NHL. Hematol Oncol. 2003 Sep;21(3):99-108 PMID: 14579238
8c. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leuk Lymphoma. 2003 Nov; 44(11): 1911-7 PMID: 14738142 | Related articles
Radiotherapies
1r. Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. [in patients with nodal bulky disease] - Eur J Haematol 2002: 68: 144-149 PDF | PDFHelp
2r. Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial.
Eur J Haematol. 2002 Mar;68(3):144-9. PMID: 12068794 PubMed
3r. Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma. Cancer. 1995 May 1;75(9):2361-7. PMID: 7712449 PubMed
|
Survival & Durable Responses
Return to top
|
1d. A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma.
Acta Oncol. 2001;40(2-3):213-23. Review. PMID: 11441933 abstract
2d. Non-Hodgkin's lymphoma: review of conventional treatments. Curr Pharm Biotechnol. 2001 Dec;2(4):279-91. PMID: 11762410 abstract
3d. Horning S, Rosenberg S: The natural history of initially untreated low-grade non-Hodgkins lymphomas. N Engl J Med 311:1471-1475, 1984.)
4d. The Clinical Significance of Molecular Response in Indolent Follicular Lymphomas
By Armando López-Guillermo, Fernando Cabanillas, Peter McLaughlin, Terry Smith, Fredrick Hagemeister, María A. Rodríguez, Jorge E. Romaguera, Anas Younes, Andreas H. Sarris, H. Alejandro Preti, William Pugh, and Ming-Seng Lee
Blood, Vol. 91 No. 8 (April 15), 1998: pp. 2955-2960 bloodjournal.org full text
5d. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leuk Lymphoma. 2003 Nov; 44(11): 1911-7 PMID: 14738142 | Related articles
|